Metrics as of 10/16/2026, 08:51 AM (Berlin time), refresh in progress.
ANI Pharmaceuticals Stock
ANI Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- CEO
- Nikhil Lalwani
- Employees
- 970
- Market cap
- $1.7 B
- IPO
- 05/05/2000
ANI Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Baudette, Minnesota, operating within the Healthcare sector. Incorporated in 2001, the company develops, manufactures, and markets both branded and generic pharmaceutical products across the United States and international markets. Its diverse…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
ANI Pharmaceuticals stock: price history
1D
+0.0%
1W
-2.2%
1M
-1.8%
6M
-10.7%
YTD
-8.4%
1Y
-21.4%
2Y
+21.2%
5Y
+87.6%
10Y
+9.9%
Next earnings date
Next earnings date
06/11/2026 (in 20 days)
Volatility around earnings
~25% stronger price swings than usual
Ask the agents about ANI Pharmaceuticals
Analyst assessment of ANI Pharmaceuticals
PRICE TARGET LOW
US$85.00
CONSENSUS
US$99.50
MEDIAN
US$97.00
PRICE TARGET HIGH
US$119.00
0
STRONG BUY
6
BUY
4
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 10/08/2026
ANI Pharmaceuticals stock metrics
P/E
14.97
P/B
2.56
EV/EBITDA
6.37
RETURN ON EQUITY
4.1%
NET MARGIN
9.3%
DEBT/EQUITY
0.55
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
85.6%
FLOAT SHARES
19,661,341
AVG. DAILY VOLUME (30D)
393,152
Insider transactions (SEC)
Lalwani Nikhil
Cook Meredith
CAREY STEPHEN P.
Lalwani Nikhil
Thoma Jeanne
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about ANI Pharmaceuticals stock
What does ANI Pharmaceuticals do?
ANI Pharmaceuticals, Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in United States.
The CEO is Nikhil Lalwani, the company employs around 970 people.
The IPO was on 05/05/2000; the stock trades on NASDAQ under the ticker ANIP.
What do analysts say about ANI Pharmaceuticals stock?
10 analysts rate the stock, the consensus is Buy (as of 10/08/2026).
The average price target is US$99.50, ranging from US$85.00 to US$119.00, with a median of US$97.00.
This is an external assessment, not a statement by Market Jury.
When does ANI Pharmaceuticals report next?
The next earnings date is 06/11/2026.
Around past earnings, price swings were roughly 25% stronger than usual.
Does ANI Pharmaceuticals pay a dividend?
No, ANI Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to ANI Pharmaceuticals?
Comparable stocks include Zoetis, Viatris, Lantheus Holdings, Amneal Pharmaceuticals, Indivior Pharmaceuticals, Eton Pharmaceuticals, Pacira BioSciences and Amphastar Pharmaceuticals.
How can I get ANI Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess ANI Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.